Economic Evaluation of Andexanet Versus Prothrombin Complex Concentrate for Reversal of Factor Xa-Associated Intracranial Hemorrhage
Stroke 52:1390-1397, Micieli, A.,et al, 2021
Cost-Effectiveness of Left Atrial Appendage Closure With the WATCHMAN Device Compared with Warfarin or Non-Vitamin K Antagonist Oral Anticoagulants for Secondary Prevention in Nonvalvular Atrial Fibrillation
Stroke 49:1464-1470, Reddy, V.Y.,et al, 2018
Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis
BMJ 359:J5058, Lopez-Lopez, J.A.,et al, 2017
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients
Stroke 47:1555-1561, Shah, A.,et al, 2016
Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation
Stroke 44:1676-1681, Harringotn, A.,et al, 2013
Dabigatran Etexilate versus Warfarin in Management of Non-Valvular Atrial Fibrillation in UK Context: Quantitative Benefit-Harm and Economic Analyses
BMJ 343:d6333, Pink, J.,et al, 2011
Cost-Effectiveness of Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation and Prior Stroke or Transient Ischemic Attack
Stroke 43:881-883, Kamel,H.,et al, 2012
Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation
Stroke 42:112-118, Mercaldi,C.J.,et al, 2011
Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation
Stroke 42:1717-1721, Jowett, S.,et al, 2011
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
JAMA 293:699-706, OBrien,C.L. &Gage,B.F., 2005
Cost-Effectiveness of Anticoagulation in Nonrheumatic A Fib in the Primary Prevention of Ischemic Stroke
Stroke 29:1827-1832, Lightowlers,S.&McGuire,A., 1998
Comparison of an Anticoagulation Clinic With Usual Medical Care: Anticoagulation Control, Patient Outcomes, and Health Care Costs
Arch Int Med 158:1641-1647, Chiquette,E.,et al, 1998
Cost-Effectiveness of Warfarin and Aspirin for Prophylaxis of Stroke in Patients with Nonvalvular Atrial Fibrillation
JAMA 274:1839-1845, Gage,B.F.,et al, 1995
Cost Effectiveness of Primary Stroke Prevention in Atrial Fibrillation
BMJ 305:1457-1460, 14451992., Gustafsson,C.,et al, 1992
Venous Thromboembolism in Stroke:Literature Review and Implications for Clinical Practice
Arch Phys Med Rehabil 73:379-391, Brandstater,M.E.,et al, 1992
Risk of Hemorrhagic Stroke With Aspirin Use
Stroke 36:1801-1807, Gorelick,P.B. &Weisman,S.M., 2005
Use of Specialized Coagulation Testing in the Evaluation of Patients with Acute Ischemic Stroke
Neurol 56:624-627, Bushnell,C.,et al, 2001
AGGRENOX: A Combination of Antiplatelet Drugs for Stroke Prevention
The Medical Letter 442:11-12, , 2000
Thienopyridines or Aspirin to Prevent Stroke and Other Serious Vascular Events in patients at High Risk of Vascular Disease?
Stroke 31:1779-1784, Hankey,G.J. et al, 2000
Treatment of Acute Ischemic Stroke
NEJM 343:710-722, Brott, T. & Bogousslavsky, J., 2000
Cost-Effectiveness of New Antiplatelet Regimens Used as Secondary Prevention of Stroke or Transient Ischemic Attack
Arch Int Med 160:2773-2778, Sarasin,F.P.,et al, 2000
Therapeutic Benefit, Aspirin Revisited in Light of the Introduction of Clopidogrel
Stroke 30:1716-1721, Gorelick,P.B.,et al, 1999
Treatment and Secondary Prevention of Stroke:Evidence, Costs, and Effects on Individuals and Populations
Lancet 354:1457-1463, Hankey,G.J.&Warlow,C.P., 1999
The Antiplatelet Effects of Ticlopidine and Clopidogrel
Ann Int Med 129:394-405, Sharis,P.J.,et al, 1998
A 79-Year Old Musician with Asymptomatic Carotid Artery Disease
JAMA 274:1383-1389, Caplan,L.R., 1995
Stroke:The Way Things Really Are
Stroke 25:1290-1294, Scheinberg,P., 1994
Cost-Effectiveness of Ticlopidine in Preventing Stroke in High-Risk Patients
Stroke 25:1149-1156, 10971994., Oster,G.,et al, 1994
Role of Ticlopidine for Prevention of Stroke
Stroke 23:912-916, Albers,G.W., 1992
Should TIA Patients Be Hospitalized or Referred to a Same-Day Clinic?
Neurol 77-2082-2088, Joshi, J.K.,et al, 2011
Effect of Urgent Treatment of Transient Ischaemic Attack and Minor Stroke on Early Recurrent Stroke (EXPRESS Study): A Prospective Population-Baed Sequential Comparison
Lancet 370:1432-1442,1398, Rothwell,P.M., et al, 2007
Patients With Transient Ischemic Attack Do Not Need to Be Admitted to Hospital for Urgent Evaluation and Treatment: Against.
Stroke 37:1139-1140,1140, Lindley,R.I., 2006
Patients With Transient Ischemic Attack or Minor Stroke Should Be Admitted to Hospital: For
Stroke 37:1137-1138,1140, Hill,M.D. &Gladstone,D.J., 2006
Is Hospitalization After TIA Cost-Effective on the Basis of Treatment With tPA?
Neurol 65:1799-1801, Nguyen-Huynh,M.N. &Johnson,S.C., 2005
The New Antiepileptic Drugs, Clinical Applications
JAMA 291:615-620, LaRoche,S.M.&Helmers,S.L., 2004
Diagnostic Testing for Coagulopathies in Patients With Ischemic Stroke
Stroke 31:3067-3078, Bushnell,C.D. & Goldstein,L.B., 2000
A Pharmacoeconomic Eval of IV Fosphenytoin (Cerebyx) vs IV Phenytoin (Dilantin) in Hosp ER Dept
Clin Therapeutics 18:953-966, Marchetti,A.,et al, 1996
Drugs for Migraine
The Medical Letter 37:17-20, , 1995
The Effect of Comb Oral Lysine Acetylsalicylate & Metoclopramide Compared w/Oral Sumatriptan for Migraine
Lancet 346:923-926, Tfelt-Hansen,P.,et al, 1995